EMA Validates MAA for Repotrectinib in ROS1+ NSCLC and NTRK+ Solid Tumors

The European Medicines Agency has validated its marketing authorization application for repotrectinib in adult patients with ROS1 TKI-naive or -pretreated locally advanced or metastatic non–small cell lung cancer harboring ROS1 fusions, as well as adult and pediatric patients with TKI-naive and pretreated NTRK-positive locally advanced or metastatic solid tumors.

Related Keywords

United States ,American ,Repotrectinib Augtyro ,Joseph Fiore ,European Medicines Agency ,Drug Administration ,Point Therapeutics Inc ,Virtual Congress ,Zai Lab ,Zai Lab Partner Turning Point Therapeutics ,International Society Of Paediatric Oncology ,Bristol Myers Squibb ,African American ,International Society ,Paediatric Oncology ,Medicines Agency ,Updated November ,Point Therapeutics ,Tyrosine Kinase Inhibitor ,Lab Partner Turning Point Therapeutics ,Lab Limited ,Turning Point Therapeutics ,Lung Cancer ,Global Oncology ,News ,The European Medicines Agency ,Repotrectinib ,Augtyro ,Non Small Cell Lung Cancer ,Nsclc ,